The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery

被引:0
|
作者
Dahlborg, SA
Petrillo, A
Roman-Goldstein, S
Doolittle, ND
Fuller, KH
Neuwelt, EA
机构
[1] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Psychol Med, Portland, OR 97201 USA
[3] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97201 USA
来源
CANCER JOURNAL | 1998年 / 4卷 / 02期
关键词
carboplatin; CNS lymphoma; cognitive function; cyclophosphamide; etoposide; germ cell tumor; methotrexate; neuropsychological assessment; primitive neuroectodermal tumor;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Radiographic tumor response and survival were evaluated in the pediatric and young adult population with germ cell tumor, primary CNS lymphoma, or primitive neuroectodermal tumor receiving intra-arterial carboplatin-or methotrexate-based chemotherapy with osmotic blood-brain barrier disruption (BBBD). PATIENTS AND METHODS Thirty-four patients with histologically confirmed germ cell tumor (n = 9), primary CNS lymphoma (n = 9), or primitive neuroectodermal tumor (n = 16) were treated at the Oregon Health Sciences University from August 1981 through April 1995. Ages ranged from 1 to 30 years (mean, 18 years). Prior treatments included cranial radiation (n = 10) and chemotherapy (n = 18). All patients underwent extensive baseline neuropsychological evaluation and follow-up evaluation upon completion of the protocol, except for two patients who declined follow-up assessment. RESULTS Six hundred and forty-five BBBD procedures were performed with no mortality. Significant complications included one episode of tonsillar herniation with no neurologic sequelae, 4% incidence of seizures, and 3% incidence of sepsis or granulocytopenic fever. Ototoxicity was seen in 61% of patients who received carboplatin chemotherapy. Eighty-two percent of the patients had an objective response to treatment, including 62% with complete response and 20% with partial response. For most patients, cognitive functioning was maintained or improved at follow-up; this pattern was statistically significant. Three of the test scores for the seven patients who did not receive radiation therapy showed a cognitive decline of at least one standard deviation. Among the nine patients who received radiation therapy before or after BBBD chemotherapy, 11 test scores showed a decline in cognitive function at one standard deviation or more. DISCUSSION Durable responses were seen in patients with germ cell tumor and primary CNS lymphoma when treated with BBBD. Primitive neuroectodermal tumor requires post-chemotherapy radiotherapy for a durable response to be attained. Ototoxicity was a major form of toxicity in the patients who received carboplatin, but with the recent introduction of sodium thiosulfate, this problem has been markedly alleviated. Favorable cognitive outcomes appeared more likely for patients treated solely with BBBD chemotherapy and not with radiotherapy. Trends in the results for this sample are similar to those of previous research showing that radiotherapy is associated with cognitive decline. Current alternatives to enhanced drug delivery after BBBD include bone marrow transplantation; however, the increment in drug delivery is less, the number of courses is limited, and the morbidity and mortality are greater for bone marrow transplant than for BBBD. The current results suggest that in future trials, irradiation may not be needed in lymphoma and may not be necessary in some CNS germ cell tumors and that more focal radiotherapy should be further assessed in localized primitive neuroectodermal tumors.
引用
收藏
页码:110 / 124
页数:15
相关论文
共 50 条
  • [1] Differences in the distribution of brain tumors by primary site in children, young adults, and adults
    Mccarthy, Bridget
    Propp, Jennifer
    NEURO-ONCOLOGY, 2008, 10 (03) : 413 - 413
  • [2] Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
    Mathieu, David
    Fortin, David
    CURRENT CLINICAL PHARMACOLOGY, 2007, 2 (03): : 197 - 211
  • [3] CHEMOTHERAPY OF PRIMARY MALIGNANT BRAIN TUMORS IN CHILDREN
    SHAPIRO, WR
    CANCER, 1975, 35 (03) : 965 - 972
  • [4] Aprepitant Reduces Chemotherapy-Induced Vomiting in Children and Young Adults With Brain Tumors
    Duggin, Kelly
    Tickle, Kelly
    Norman, Gina
    Yang, Jie
    Wang, Chong
    Cross, Shane J.
    Gajjar, Amar
    Mandrell, Belinda
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2014, 31 (05) : 277 - 283
  • [5] Neoadjuvant chemotherapy for brain tumors in infants and young children
    Iwama, Junya
    Ogiwara, Hideki
    Kiyotani, Chikako
    Terashima, Keita
    Matsuoka, Kentaro
    Iwafuchi, Hideto
    Morota, Nobuhito
    Journal of Neurosurgery-Pediatrics, 2015, 15 (05) : 488 - 492
  • [6] The pathophysiology of primary bone tumors in young adults and children
    Miller, Ira
    Kent, Paul M.
    Finney, Joseph
    CURRENT PROBLEMS IN CANCER, 2013, 37 (04) : 172 - 180
  • [7] RFQMR THERAPY IN BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS
    Nayar, G. S.
    Kumar, Rajah Vijay
    Nair, Anjana
    Augustus, Meena
    NEURO-ONCOLOGY, 2016, 18 : 163 - 163
  • [8] Salvage therapy after postoperative chemotherapy for primary brain tumors in infants and very young children
    Fisher, PG
    Needle, MN
    Cnaan, A
    Zhao, HQ
    Geyer, JR
    Molloy, PT
    Goldwein, JW
    Herman-Liu, AB
    Phillips, PC
    CANCER, 1998, 83 (03) : 566 - 574
  • [9] MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children
    Joann L. Ater
    Jan van Eys
    Shiao Y. Woo
    Bartlett Moore III
    Donna R. Copeland
    Janet Bruner
    Journal of Neuro-Oncology, 1997, 32 : 243 - 252
  • [10] MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children
    Ater, JL
    vanEys, J
    Woo, SY
    Moore, B
    Copeland, DR
    Bruner, J
    JOURNAL OF NEURO-ONCOLOGY, 1997, 32 (03) : 243 - 252